How to manage toxicities associated with bispecific antibody therapy for MM in community practice

The Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, ES. We asked about the management of toxicities associated with bispecific antibody therapy for multiple myeloma (MM) in community practice.

In this interview, Mateos discusses practical considerations for the management of adverse events (AEs) associated with bispecific antibodies in MM. Mateos outlines how to recognize and manage cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), as well as strategies to mitigate infection risk. Mateos also discusses the management of skin, nail, and oral toxicities associated with G-protein coupled receptor family C group 5 member D (GPRC5D)-directed bispecific antibodies.

Intended for healthcare professionals. This educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.